10-Q: Quarterly report
8-K: AGILE THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
10-K/A: Annual report (Amendment)
Agile Therapeutics | 8-K: Current report
Agile Therapeutics | 10-K: Annual report
Agile Therapeutics | 8-K: AGILE THERAPEUTICS REPORTS FOURTH QUARTER & FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Agile Therapeutics | 8-K: Current report
Agile Therapeutics | 8-K: Current report
Agile Therapeutics | 8-K: Current report
Agile Therapeutics | 424B5: Prospectus
Agile Therapeutics | 424B5: Prospectus
Agile Therapeutics | 8-K: Current report
Agile Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(1.8%),Lind Global Partners II LLC(1.8%), etc.
Agile Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Agile Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(0.9%),Daniel B. Asher(0.9%), etc.
Agile Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Agile Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Agile Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Agile Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
Agile Therapeutics | 8-K: Current report
No Data